Publications

5808 Results

Outcomes and toxicity in African-American an d caucasian patients receiving adjuvant chemotherapy for colon cancer: a secondary analysis of INT-0089

Authors
AD McCollum;PJ Catalano;DG Haller;RJ Mayer;JS Macdonald
Journal / Conference
Proc of the American Society of Clinical Oncology 20:133a(#528)
Year
2001
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-8899 (INT-0089)

Adjuvant chemo and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827.

Authors
SE Rivkin;S Green;SJ Altman;JJ Costanzi;AB Cruz;C Giarritta;WR Jewell;RM O'Bryan
Journal / Conference
Proc of the American Society of Clinical Oncology 20:27a(#105)
Year
2001
Research Committee(s)
Breast
Study Number(s)
SWOG-7827

Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III study: final report

Authors
M Al-Sarraf;M Le Blanc;P Giri;K Fu;J Cooper;T Vuong;A Forastiere;G Adams;W Sakr;D Schuller;F Ensley
Journal / Conference
Proc of the American Society of Clinical Oncology 20:227a(#905)
Year
2001
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817)

Significant impact of HLA classI alleles on outcome in T3NO melanoma patients treated with melacine (MEL): an allogeneic melanoma cell lysate vaccine: prospective analysis of Southwest Oncology Group (SWOG)-9035.

Authors
JA Sosman;JM Unger;PY Liu;L Flaherty;R Kempf;J Thompson;V Sondak
Journal / Conference
Proc of the American Society of Clinical Oncology 20:351a(#1402)
Year
2001
Research Committee(s)
Melanoma
Study Number(s)
SWOG-9035

SELECT: The next prostate cancer prevention trial

Authors
EA Klein;IM Thompson;SM Lippman;PJ Goodman;D Albanes;PR Taylor;C Coltman
Journal / Conference
Journal of Urology 166:1311-1315
Year
2001
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

The web-based management of the selenium and vitamin E cancer prevention trial

Authors
PA Shaw;PJ Goodman;J Brace
Journal / Conference
Controlled Clinical Trials 22(2S):57S(#P06)
Year
2001
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Promoting adherence to the prostate cancer prevention trial end of study biopsy requirement

Authors
AM Ryan;P Goodman;S Hill;C Moinpour
Journal / Conference
Controlled Clinical Trials 22(2S):88S(#P71)
Year
2001
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

A phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for Stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391)

Authors
OW Press;M LeBlanc;A Lichter;TH Wasserman;J Unger;T Miller;RI Fisher
Journal / Conference
Leukemia & Lymphoma 42(Suppl.2):52(#P-089)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9133

A phase III trial of CHOP followed by Bexxar (tositumomab and Iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911)

Authors
OW Press;JM Unger;RM Braziel;DG Maloney;ML LeBlanc;TM Grogan;TP Miller;RI Fisher
Journal / Conference
Blood 98(11):843a-844a(#3504)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
S9911

Dose-intense CHOPx2 therapy of intermediate grade lymphoma -- a phase II study of the Southwest Oncology Group (SWOG)

Authors
DW Blayney;M LeBlanc;RI Fisher
Journal / Conference
Blood 98(11):343a(#1448)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9349